Market Place
Sourcing Support
Airway Therapeutics Launches Phase 3 Trial Of Zelpultide Alfa
15 Oct 2024 //
BUSINESSWIRE
Airway Wins 2024 ATS Whitsett Award for Zelpultide Alfa
24 Jun 2024 //
BUSINESSWIRE
Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa
05 Jun 2023 //
BUSINESSWIRE
Airway Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa
11 Apr 2023 //
BUSINESSWIRE
Airway doses first subject in bronchopulmonary dysplasia trial in Spain
04 Oct 2022 //
CLINICALTRIALSARENA
Airway Opens Trial Sites and Treats First Patient in P1b Study of AT-100
03 Oct 2022 //
PRNEWSWIRE
Airway Tx Begins Dosing in P1b Trial of AT-100 in Bronchopulmonary Dysplasia
31 Mar 2022 //
PRNEWSWIRE
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100
26 Aug 2021 //
PRNEWSWIRE
US FDA accepts Airway Therapeutics’ IND application to develop AT-100
13 Apr 2021 //
PHARMBIZ
FDA accepts Airway Therapeutics’ IND application for Covid-19
13 Apr 2021 //
PHARACEUTICAL-TECHNOLOGY
FDA Accepts IND for Airway Therapeutics’ Treatment for Severe COVID-19 Patients
13 Apr 2021 //
PHARTECH
Airway Announces FDA Acceptance of IND for AT-100`s Second Indication
13 Apr 2021 //
BIOSACE
US FDA accepts Airway Therapeutics’ IND application to develop AT-100
30 Mar 2021 //
PHARMABIZ
Airway Therapeutics Announces FDA Acceptance of IND for AT-100 )
26 Mar 2021 //
PRNEWSWIRE
Airway Therapeutics Announces FDA Acceptance of IND for AT-100
25 Mar 2021 //
PRNEWSWIRE
Airway , Celonic collaborate to produce AT-100 promising therapeutic candidate
21 May 2020 //
PHARMABIZ
Airway Therapeutics and Celonic Group Collaborate to Produce AT-100
20 May 2020 //
PRNEWSWIRE
Airway Therapeutics Announces NIH Filing to Evaluate AT-100
10 Mar 2020 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.